Skip to content
← All treatment topics

TREATMENT READING

Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Treatment of Childhood CNS Atypical Teratoid/Rhabdoid Tumor

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 3, 2025. Captured 2026-09-09.

An evidence-based standard treatment for children with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT) has not yet been defined. Given the highly aggressive nature of the tumor, most patients have been treated with intensive multimodality therapy. However, the extent of treatment, particularly for radiation therapy, is limited because of the young age of most patients.

Treatment options for newly diagnosed CNS AT/RT include the following:

Surgery, chemotherapy, and radiation therapy (multimodality therapy).

Sources: Surgery, chemotherapy, and radiation therapy (multimodality therapy)

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment of Childhood CNS Atypical Teratoid/Rhabdoid Tumor

Surgery, Chemotherapy, and Radiation Therapy (Multimodality Therapy)

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 3, 2025. Captured 2026-09-09.

The extent of surgical resection may affect survival. Data from the Central Nervous System Atypical Teratoid/Rhabdoid Tumor Registry (AT/RT Registry) suggest that patients who have had a complete resection may have a longer median survival. However, complete surgical resection is often difficult because of the invasive nature of the tumor.[1]

Sources: 1

Chemotherapy has been the main adjuvant therapy for very young children with AT/RT. Cooperative group studies that included children younger than 36 months demonstrated poor survival with standard chemotherapeutic regimens alone.[2] The Children’s Cancer Group reported a 2-year event-free survival (EFS) rate of 14% for 28 children younger than 36 months who were treated with multiagent chemotherapy.[3]

Sources: 2 · 3

Intensive regimens that use varying combinations of high-dose chemotherapy,[4][Level of evidence C1]; [5,6][Level of evidence C2] intrathecal chemotherapy, and radiation therapy have led to prolonged survival for some patients.

Sources: 4 · Level of evidence C1 · 5 · 6 · Level of evidence C2

Only two prospective trials for children with CNS AT/RT have been completed. In an institutional prospective trial, children were treated with a modified Intergroup Rhabdomyosarcoma Study-III (IRS-III) protocol, using intrathecal chemotherapy and radiation therapy. Of the subset of 20 children who completed therapy, the 2-year progression-free survival (PFS) rate was 53%, and the overall survival (OS) rate was 70%. Survival was better for patients who had a complete resection.[7][Level of evidence C1] In the Children's Oncology Group (COG) ACNS0333 (NCT00653068) study, patients were treated with intensive induction chemotherapy, followed by high-dose chemotherapy with autologous stem cell rescue and radiation therapy. The 4-year PFS rate was 37%, and the OS rate was 43%.[8][Level of evidence B4]

Sources: 7 · Level of evidence C1 · ACNS0333 (NCT00653068) · 8 · Level of evidence B4

Thirteen patients in the AT/RT Registry were treated with high-dose chemotherapy with hematopoietic stem cell rescue as part of initial therapy.[1] Four of these patients, two of whom also received radiation, were alive without progressive disease 21.5 to 90 months after diagnosis at last report. Of 15 evaluable children (all younger than 32 months at diagnosis) who were on a chemotherapy Head Start III protocol, 2 survived for more than 47 months.[9][Level of evidence C1]

Sources: 1 · 9 · Level of evidence C1

Radiation therapy appears to have a positive impact on survival for patients with AT/RT.[10,11]

Sources: 10 · 11

Evidence (radiation therapy):

Of the 42 patients in the AT/RT Registry, 13 (31%) received radiation therapy in addition to chemotherapy as part of their primary therapy.[1] The radiation field was to the primary tumor bed in nine children, and the radiation field was to the tumor bed and the craniospinal axis in four children.

Sources: 1

Of the 42 patients in the AT/RT Registry, 13 (31%) received radiation therapy in addition to chemotherapy as part of their primary therapy.[1] The radiation field was to the primary tumor bed in nine children, and the radiation field was to the tumor bed and the craniospinal axis in four children.

The median survival of these patients was 48 months, compared with 16.75 months for all patients in the registry.

In a retrospective series of 31 patients with AT/RT from the St. Jude Children's Research Hospital, the following results were reported:[12]

Sources: 12

In a retrospective series of 31 patients with AT/RT from the St. Jude Children's Research Hospital, the following results were reported:[12]

The 2-year EFS rate was 78% for patients older than 3 years, which was considerably better than the EFS rate of 11% for patients younger than 3 years.

All but one of the surviving patients (seven of eight) in the older group received craniospinal irradiation and intensive chemotherapy with hematopoietic stem cell transplant.

Only 3 of the 22 younger patients received any form of radiation therapy, 2 of whom were disease free.

In a Surveillance, Epidemiology, and End Results (SEER) Program registry review, radiation therapy was associated with improved survival in children younger than 3 years.[13]

Sources: 13

In the European Registry for rhabdoid tumors series, the following results were observed:[14][Level of evidence C1]

Sources: 14 · Level of evidence C1

In the European Registry for rhabdoid tumors series, the following results were observed:[14][Level of evidence C1]

Radiation therapy was also associated with improved survival, with a 6-year OS rate of 66% (± 0.1%) in patients who received this treatment.

The significant benefit of radiation therapy was corroborated in an extension of this series.[15]

Sources: 15

Evidence (multimodality therapy):

The IRS-III study used radiation therapy, intrathecal methotrexate, cytarabine, hydrocortisone, and systemic multiagent chemotherapy. The results of this small retrospective series were encouraging,[16,17] leading to the first prospective study of multimodality treatment in this group of patients.

Sources: 16 · 17

On the basis of the previous pilot series, a prospective multi-institutional trial was conducted for children with newly diagnosed CNS AT/RT. Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes. Radiation therapy was either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on the child's age and extent of disease at diagnosis.[7]

Sources: 7

On the basis of the previous pilot series, a prospective multi-institutional trial was conducted for children with newly diagnosed CNS AT/RT. Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes. Radiation therapy was either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on the child's age and extent of disease at diagnosis.[7]

The 2-year PFS rate was 53% (± 13%), and the 2-year OS rate was 70% (± 10%).

Results were most favorable for children who were older, had a gross-total resection, and had no metastatic disease at presentation.

Six of the eight children without progressive disease at the time of the report had received conformal radiation therapy, and two children had received craniospinal radiation therapy. Seven children had a gross-total resection, and only one child had metastatic disease (this child had persistent, stable disease 1.5 years from diagnosis).

The COG performed a prospective single-arm study of 65 children. Fifty-four of the children were younger than 36 months and received two courses of methotrexate, cyclophosphamide, cisplatin, and etoposide followed by three courses of high-dose carboplatin and thiotepa supported by peripheral stem cell rescue. For patients with nondisseminated disease, focal involved-field radiation therapy was mandated after either induction or consolidation, depending on age. For patients with disseminated disease, craniospinal radiation at the end of therapy was recommended but not mandated.[8]

Sources: 8

The COG performed a prospective single-arm study of 65 children. Fifty-four of the children were younger than 36 months and received two courses of methotrexate, cyclophosphamide, cisplatin, and etoposide followed by three courses of high-dose carboplatin and thiotepa supported by peripheral stem cell rescue. For patients with nondisseminated disease, focal involved-field radiation therapy was mandated after either induction or consolidation, depending on age. For patients with disseminated disease, craniospinal radiation at the end of therapy was recommended but not mandated.[8]

For all patients, the 4-year EFS rate was 37%, and the 4-year OS rate was 43%.

For children younger than 36 months at diagnosis, the 4-year EFS rate was 35%, compared with 6.4% in a historical cohort of patients who received chemotherapy alone (P < .0005).

For the 11 children aged 36 months or older at diagnosis, the 4-year EFS rate was 48%, and the 4-year OS rate was 57%.

Toxicity from this regimen was significant. Four treatment-related deaths (6% of the patients) resulting from sepsis, respiratory failure, or CNS necrosis were reported.

On the basis of the two prospective studies summarized above, multimodality therapy with surgery, radiation therapy, and chemotherapy seems to be the best treatment to optimize the survival of children with AT/RT. However, toxicities can be significant, and the most effective regimen and the optimal sequencing of therapies still need to be determined.

Health professional · Treatment of Childhood CNS Atypical Teratoid/Rhabdoid Tumor

Treatment Options Under Clinical Evaluation

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 3, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children’s Oncology Group, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children’s Oncology Group · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional

Treatment of Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 3, 2025. Captured 2026-09-09.

There is no standard treatment for children with recurrent central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT), and their outcomes are poor.[1]

Sources: 1

Trials of molecularly targeted therapy are ongoing. In a study of the EZH2 inhibitor tazemetostat in adult patients with epithelioid sarcoma and non-CNS malignant rhabdoid tumors with SMARCB1 or SMARCA4 loss, prolonged stable disease and objective responses were observed.[2] In the National Cancer Institute (NCI)–Children's Oncology Group Pediatric MATCH APEC1621C (NCT03213665) trial, eight children with AT/RT received tazemetostat. One patient demonstrated disease stabilization.[3][Level of evidence B4]

Sources: 2 · APEC1621C (NCT03213665) · 3 · Level of evidence B4

Stereotactic radiation therapy/radiosurgery or focal radiation therapy can also be considered for the treatment of children with recurrent disease.[4]

Sources: Stereotactic radiation therapy/radiosurgery · 4

Patients or families who desire additional disease-directed therapy should consider entering trials of novel therapeutic approaches because no standard agents have demonstrated clinically significant activity.

Regardless of whether a decision is made to pursue disease-directed therapy at the time of progression, palliative care remains a central focus of management. This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.

Health professional · Treatment of Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor

Treatment Options Under Clinical Evaluation

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 3, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children’s Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children’s Oncology Group (COG) · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

PEPN2121 (NCT05286801) (Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1- or SMARCA4-Deficient Tumors): This study is evaluating the combination of a PD-L1 targeting antibody (atezolizumab) with a TIGIT targeting antibody (tiragolumab) for patients with SMARCB1- or SMARCA4-deficient tumors. Patients with AT/RT may be eligible for this study.

Sources: PEPN2121 (NCT05286801)

For patients · General Information About Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

If your child has been diagnosed with AT/RT, you likely have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis.

The prognosis depends on:

whether your child has certain inherited gene changes

whether the tumor has certain gene changes

your child's age

the amount of tumor remaining after surgery

whether the cancer has spread to other parts of the brain and spinal cord or to the kidney at the time of diagnosis

whether the cancer has just been diagnosed or has recurred (come back)

No two people are alike, and responses to treatment can vary greatly. Your child's cancer care team is in the best position to talk with you about your child's prognosis.

For patients

Treatment Option Overview

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

There are different types of treatment for children with central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT).

Children with AT/RT should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

Childhood brain tumors may cause symptoms that begin before the cancer is diagnosed and continue for months or years.

The following types of treatment may be used:

The following types of treatment may be used:

Surgery

Chemotherapy

Radiation therapy

Stem cell transplant

Clinical trials

Treatment for childhood CNS AT/RT may cause side effects.

Follow-up care may be needed.

Resources and support are available to help you cope with your child's cancer.

For patients · Treatment Option Overview

There are different types of treatment for children with central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT).

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

There are different types of treatment for children with AT/RT. You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the cancer is located and your child's age and overall health.

Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, see our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

For patients · Treatment Option Overview

Children with AT/RT should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of AT/RT. The pediatric oncologist works with other health care providers who are experts in treating children with CNS cancer and also specialize in other areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric neurosurgeon

Sources: neurosurgeon

radiation oncologist

Sources: radiation oncologist

neurologist

Sources: neurologist

pediatric nurse specialist

Sources: pediatric nurse specialist

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

social worker

Sources: social worker

geneticist or genetic counselor

Sources: geneticist · genetic counselor

fertility specialist

Sources: fertility specialist

For patients · Treatment Option Overview

Childhood brain tumors may cause symptoms that begin before the cancer is diagnosed and continue for months or years.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

Symptoms caused by the tumor may begin before diagnosis. These signs or symptoms may continue for months or years. It is important to talk with your child's doctors about symptoms caused by the tumor that may continue after treatment.

Sources: Symptoms

For patients · Treatment Option Overview

The following types of treatment may be used:

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment may be used:

Surgery

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

Surgery is used to treat CNS AT/RT. Learn more about how this tumor is diagnosed.

Sources: diagnosed

After the doctor removes all the cancer that can be seen at the time of the surgery, most children will receive chemotherapy and possibly radiation therapy to try to kill any cancer cells that are left. Treatment given after surgery to lower the risk that the cancer will come back is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment may be used:

Chemotherapy

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

Chemotherapy uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cells or stops them from dividing. Chemotherapy may be given with other types of treatments.

Chemotherapy for AT/RT is injected into a vein. When given this way, the drugs enter the bloodstream and can reach tumor cells throughout the body. High doses of some chemotherapy drugs given into a vein can cross the blood-brain barrier and reach the tumor. Chemotherapy for AT/RT is also placed directly into the cerebrospinal fluid (intrathecal chemotherapy). Combination chemotherapy uses more than one anticancer drug.

Sources: injected · bloodstream · doses · cerebrospinal fluid · intrathecal chemotherapy · Combination chemotherapy

Chemotherapy drugs used alone or in combination to treat AT/RT in children include:

carboplatin

Sources: carboplatin

cisplatin

Sources: cisplatin

cyclophosphamide

Sources: cyclophosphamide

cytarabine

Sources: cytarabine

etoposide

Sources: etoposide

methotrexate

Sources: methotrexate

thiotepa

Sources: thiotepa

Other chemotherapy drugs not listed here may also be used.

Learn more about how chemotherapy works, how it is given, and common side effects at Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

Radiation therapy

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Because radiation therapy can affect growth and brain development in young children, especially children who are 3 years old or younger, the dose of radiation therapy may be lower than in older children.

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Treatment Option Overview / The following types of treatment may be used:

Stem cell transplant

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. This treatment destroys healthy cells, including blood-forming cells. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: blood · bone marrow · infusion

For patients · Treatment Option Overview / The following types of treatment may be used:

Clinical trials

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can find clinical trials for people with atypical teratoid/rhabdoid tumor at Treatment Clinical Trials for Atypical Teratoid/Rhabdoid Tumor or use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: Treatment Clinical Trials for Atypical Teratoid/Rhabdoid Tumor · clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for childhood CNS AT/RT may cause side effects.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

physical problems

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer)

Sources: second cancers

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some of the tests that were done to diagnose the cancer may be repeated. Some tests will be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

Sources: recurred

For patients · Treatment Option Overview

Resources and support are available to help you cope with your child's cancer.

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

When your child has cancer, every member of the family needs support. Taking care of yourself during this difficult time is important. Reach out to your child's treatment team and to people in your family and community for support. To learn more, see Support for Families: Childhood Cancer and the booklet Children with Cancer: A Guide for Parents.

Sources: Support for Families: Childhood Cancer · Children with Cancer: A Guide for Parents

For patients

Treatment of Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

There is no standard treatment for children with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT). Because AT/RT is fast-growing, a combination of treatments is usually given.

Sources: standard treatment · central nervous system · atypical teratoid/rhabdoid tumor · combination

After surgery to remove the tumor, treatment for AT/RT may include combinations of:

chemotherapy

Sources: chemotherapy

radiation therapy

Sources: radiation therapy

high-dose chemotherapy with stem cell transplant

Sources: high-dose chemotherapy · stem cell transplant

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

There is no standard treatment for children with recurrent central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT).

Sources: standard treatment · recurrent

Treatment for recurrent childhood AT/RT may include:

radiation therapy

Sources: radiation therapy

palliative treatment to improve quality of life

Sources: palliative treatment · quality of life

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

NCT00653068 · COMPLETED · phase3

Childhood Atypical Teratoid/Rhabdoid Tumor

ClinicalTrials.gov record

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

NCT03213665 · COMPLETED · phase2

Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV...

ClinicalTrials.gov record

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

NCT03043391 · COMPLETED · phase1

Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain,...

ClinicalTrials.gov record

Disease and treatment settings

Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Disease and treatment setting

Central Nervous System Atypical Teratoid/Rhabdoid Tumor in children and adolescents

recurrent Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor

Disease and treatment setting

Treatment of Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor